Ocular Cicatricial Pemphigoid

被引：1

作者：

Mousa, Hazem M. ^{[1
]}

Starr, Christopher E. ^{[2
]}

Soifer, Matias ^{[1
]}

Savarain, Christian ^{[1
]}

Perez, Victor L. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27705 USA

[2] Weill Cornell Med Coll, New York Presbyterian Hosp, Dept Ophthalmol, New York, NY 10065 USA

来源：

CURRENT OPHTHALMOLOGY REPORTS | 2020年 / 8卷 / 01期

关键词：

Ocular cicatricial pemphigoid; Mucous membrane pemphigoid; Cicatricial pemphigoid; Ocular immunology; Autoimmune eye disease; NECROSIS-FACTOR-ALPHA; CYCLOPHOSPHAMIDE; THERAPY; METHOTREXATE; MANAGEMENT; CONSENSUS; DISEASE;

D O I：

10.1007/s40135-020-00226-0

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose of ReviewThis review offers an informed insight on the pathophysiology of ocular cicatricial pemphigoid in addition to up-to-date recommendations for monitoring and management.Recent FindingsSystemic immunosuppression is required for treatment of ocular cicatricial pemphigoid when there is high suspicion, even in the absence of diagnostic findings on biopsy. New therapeutic modalities continue to emerge and provide promising results. In addition, improved options for adjunctive care are also available.SummaryOcular cicatricial pemphigoid is a systemic illness and a subset of mucous membrane pemphigoid that primarily affects the ocular surface. It involves a progressive and potentially blinding course of disease. Diagnosis remains challenging and mainly depends on clinical suspicion with the aid of laboratory testing. Multiple treatment modalities have emerged for management mainly consisting of systemic immunosuppression for disease control in addition to adjunctive management for alleviating symptoms and preventing complications.

引用

页码：11 / 18

页数：8

共 38 条

[31] Immunosuppressive therapy for ocular mucous membrane pemphigoid - Strategies and outcomes [J].

Saw, Valerie P. J. ;

Dart, John K. G. ;

Rauz, Saaeha ;

Ramsay, Andrew ;

Bunce, Catey ;

Xing, Wen ;

Maddison, Patricia G. ;

Phillips, Melanie .

OPHTHALMOLOGY, 2008, 115 (02) :253-261

[32] Ocular and oral pemphigus - Report of a case with anatomic findings in the eyeball [J].

Smith, RC ;

Myers, EA ;

Lamb, HD .

ARCHIVES OF OPHTHALMOLOGY, 1934, 11 (04) :635-640

[33] Profile of Local Interleukin Expression in a Cohort of Ocular Cicatricial Pemphigoid Patients [J].

Suelves, Ana M. ;

Zhao, Tong Z. ;

Siddique, Sana S. ;

Foster, C. Stephen .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2012, 53 (13) :8112-8117

[34] IMPROVED DETECTION OF DISEASE PROGRESSION IN OCULAR CICATRICIAL PEMPHIGOID [J].

TAUBER, J ;

JABBUR, N ;

FOSTER, CS .

CORNEA, 1992, 11 (05) :446-451

[35] Ocular cicatricial pemphigoid antigen: Partial sequence and biochemical characterization [J].

Tyagi, S ;

Bhol, K ;

Natarajan, K ;

LivirRallatos, C ;

Foster, CS ;

Ahmed, AR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14714-14719

[36]

WOODSON LC, 1982, J PHARMACOL EXP THER, V222, P174

[37] Mucous membrane pemphigoid: management of advanced ocular disease with intravenous cyclophosphamide and amniotic membrane transplantation [J].

Yesudian, PD ;

Armstrong, S ;

Cawood, JI ;

Allan, RB ;

Mendelsohn, SS ;

Kaye, SB .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) :692-694

[38] Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study [J].

You, Caiyun ;

Lamba, Neerav ;

Lasave, Andres F. ;

Ma, Lina ;

Diaz, Mikhail Hernandez ;

Foster, C. Stephen .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (06) :1221-1228

← 1 2 3 4 →